Milatuzumab

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Milatuzumab (hLL1; MEDI-115) 是一种人源化抗 CD74 单克隆抗体。CD74 是一种完整的膜蛋白，与促进 B 细胞生长和存活有关。Milatuzumab 导致自由基氧的产生和线粒体膜电位的丧失。 Milatuzumaba 还降低 CD20/CD74 聚集体和细胞粘附，从而导致细胞死亡。

Milatuzumab (hLL1; MEDI-115) is a humanized anti-CD74 monoclonal antibody. CD74, a integral membrane protein, is associated with the promotion of B-cell growth and survival. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death.

Western Blot AnalysisCell Line:Jeko and Mino cells Concentration:5 μg/mL Incubation Time:4 hours Result:Insignificant down-regulation of antiapoptotic proteins, such as Bax, Bcl-2, Bcl-xL, and Mcl-1.Cell Viability Assay Cell Line:MCL cell lines and primarypatient tumor cells Concentration:5 μg/mL Incubation Time:8, 24, and 48 hoursResult:Resulted in cell death of Jeko, Mino, SP-53, Rec-1, HBL-2, and Granta cells. Immunofluorescence Cell Line:Jeko, Mino, and SP-53 cells Concentration:5 μg/mL; with or without 10 mM N-acetylcysteine (HY-B0215) for 1.5 h Incubation Time:0.5, 1, 1.5, and 2 hours Result:Increased ROS generation as early as 0.5 hours, while peaking at 1 to 1.5 hours and reducing at 2 hours.Therefore, it resulted cell death, but reserved by nonspecific ROS scavenger.

Animal Model:Jeko mouse model Dosage:15 mg/kg/day; with or without 15 mg/kg Rituximab Administration:Intraperitoneal injection; once every 3 days, starting at day 15 after engraftment Result:Resulted the mean survival for the combination treated group of 44.5 days, compared with 33.5 days for Milatuzumaba treated, 28 days for control.

——

Others

Other Targets

Others

——

——

899796-83-9

——

>98% (HPLC)

——

——

——

(-20℃)

With Ice Pack

≥ 2 years